Teva Pharmaceutical Industries has agreed to pay $20 million to settle claims by direct purchasers of Shire’s ADHD drug Intuniv to settle claims that Teva’s predecessor, Actavis, and Shire delayed launch of a generic version of the drug with an illegal patent lawsuit settlement.
In a filing Tuesday in federal court in Boston, the direct purchasers, led by Meijer, said the deal was “the result of good faith, arms’-length negotiations over a period of weeks” and “a fair settlement and in the best interests of the direct purchaser class.”
To read the full story on Westlaw Today, click here: bit.ly/2F0xPPw
Our Standards: The Thomson Reuters Trust Principles.